Morgan Stanley issued a wave of upgrades and downgrades in the pharmaceutical and medical device arena.

Analysts upgraded Zimmer Holdings, Inc. ZMH 1.39% from Equal-weight to Overweight. Zimmer Holdings designs and produces orthopedic reconstructive devices, implants and related surgical products. Morgan Stanley issued a $134 price target.

Analysts upgraded C R Bard Inc BCR 0.34% from Underweight to Equal-weight. C R Bard designs and produces medical, surgical, diagnostic and patient care devices. Morgan Stanley issued a $187 price target.

Morgan Stanley upgraded Hill-Rom Holdings, Inc. HRC 0.06% from Underweight to Equal-weight. Hill-Rom manufactures hospital equipment such as beds and stretchers.

Morgan Stanley upgraded Regeneron Pharmaceuticals Inc REGN 0.5% from Equal-weight to Overweight. Regeneron researches, develops, and produces medicines to treat serious medical conditions. Analysts set a $485 price target.

Teleflex Incorporated TFX 0.12% was downgraded from Overweight to Equal-weight. The company produces single-use medical devices that aid in diagnostic and therapeutic procedures. Morgan Stanley’s target for Teleflex is $127.

Alexion Pharmaceuticals, Inc. ALXN 0.23% was also downgraded from Overweight to Equal-weight. Alexion develops therapeutic products for the treatment of diseases in the areas of hematology, nephrology, neurology, metabolic disorders, oncology and ophthalmology. Morgan Stanley’s new price target for Alexion is $202.

Finally, Morgan Stanley downgraded…

Read the rest of this article (and all my other articles) for free on Benzinga by clicking here

Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!